5-Alpha-reductase deficiency in a Saudi 'girl'

Sir,

5-Alpha-reductase deficiency is a rare but well recognised cause of familial male pseudohypermallism. So far, this disorder has been described in about 52 families from different parts of the world.¹ Most of these patients are clustered in three kindreds in the Dominican Republic,² Turkey,³ and New Guinea.⁴ There are a few reports of 5-alpha-reductase deficiency in children of Ashkenazic background.⁵ To our knowledge there are only two reports of this disease from the Arabian Gulf region.¹,⁶ We would like to report this disorder in a Saudi child.

A 14-year-old Saudi 'girl', born of consanguineous parents was referred to us for investigation for lack of breast development and primary amenorrhoea. Mild clitoromegaly was observed in this child at birth but was not investigated further. She was operated twice elsewhere for bilateral inguinal hernia. Sonogram confirmed a normal male genotype. During the six months prior to presentation, she was noted to have significant muscular development and showed interest in active sports. Family history was negative for any ambiguity in sexual development. On examination, she had a muscular build, pubic hair (Tanners P3) without any axillary or facial hair, or temporal recession of scalp hair. There was no sign of breast development. The external genitalia assessment revealed a 3-cm phallus, without urethral opening, partial posterior fusion of the urogenital sinus and lack of scrotalisation of labial folds. Sinogram confirmed a normal male genital tract. Chromosome analysis revealed a 46 XY pattern. Serum hormone profile showed luteinising hormone 15 IU/l (normal 2–14 IU/l), follicle-stimulating hormone 9 IU/l (1–10 IU/l), testosterone 16.6 nmol/l (10.4–34.3 nmol/l), dihydrotestosterone 0.36 nmol/l (1.3–1.96 nmol/l), testosterone/dihydrotestosterone ratio 46.2 (≤16), prolactin 888 pmol/l (44–932 pmol/l), oestradiol 102 pmol/l (51–346 pmol/l), dehydroepiandrosterone sulphate 4.8 µmol/l (4.8–24.3 µmol/l), and cortisol (08.00 h) 386 nmol/l (137–687 nmol/l). All normal ranges are of an adult male.

With a 46 XY chromosomal pattern, serum testosterone in the adult male range, a testosterone/dihydrotestosterone ratio of 46 and suggestive pubertal events, the diagnosis of 5-alpha-reductase deficiency was made in this child. To prevent further virilisation and changes in sexual behaviour, early laparotomy for removal of 'hidden testes' was advised. In spite of repeated counselling for six months, however, the family was undecided on the final sex of the child and did not give consent for surgical intervention. Later, she was lost to our follow-up. By reporting this patient, we stress the significance of investigation of any genital ambiguity, however mild it may be, in the neonatal period itself. This report also highlights the importance of evaluation for male pseudohypermallism in a 'female' child with inguinal masses or hernias. If proper attention had been given to these problems in this child with 5-alpha-reductase deficiency at an earlier stage, the psychological problems of late pubertal development could have been avoided.

JOHN PUNNPOSE
KS MATHIW
HASSAN P AHMED
Department of Internal Medicine, Al-Ain Hospital, Al-Ain, United Arab Emirates

Side-effects of coumarin

Sir,

Coumarin, a drug acting on macrophages and lymphatic tissue and which is not licensed for use in the UK has been promoted as a treatment for oedematous states which are unresponsive to treatment with hypoproteinaemia.¹ The usual dosage is 200 mg daily (Hamilton Pharmaceuticals Pty Ltd, Adelaide, Australia).

Toxicity is rare with elevation of liver enzymes in 0.37% of patients, probably as an idiosyncratic immune reaction.² We here report a severe hepatic reaction to this drug.

A 49-year-old woman with chronic right leg lymphoedema (which had been comprehensively investigated with negative results) had been given coumarin 400 mg daily for five months by a medical relative who had imported the drug from Australia. For many years she had used salbutamol and beclomethasone inhalers for asthma and frusmodine and chlorthalidone for the oedema. She presented with a six-day history of malaise, sore throat and icterus for one day. She had been given penicillin V for four days prior to admission.

Investigation showed a bilirubin of 119 µmol/l (normal less than 17 µmol/l), an alanine transaminase of 5577 IU/l (normal less than 40 IU/l) and an alkaline phosphatase of 283 IU/l (normal less than 125 IU/l). All tests for infectious agents including hepatitis A, B, C, and E, Epstein–Barr virus, cytomegalovirus and toxoplasmosis were negative. Coumarin was discontinued and all biochemical abnormalities had resolved five weeks later.

To our knowledge this is the only report of severe hepatotoxicity associated with coumarin. The highest alanine transaminase previously recorded is 960 IU/l and the Australian manufacturers of coumarin are aware of two other similar occurrences.

Learning points

- coumarin may cause severe hepatitis
- international enquiries may have to be made to obtain relevant information regarding certain drugs

Two lessons emerge. Firstly, coumarin may occasionally cause severe hepatotoxicity. Secondly, there is a global market for therapeutic substances of all sorts and it may be necessary to make international enquiries to obtain relevant information regarding non-licensed drugs.

LEWIS MORRISON
PHILIP D WELSBY
The City Hospital
Edinburgh EH10 6SB, UK